18:56 , Aug 31, 2018 |  BC Week In Review  |  Company News

Gritstone files for IPO, forges deal with bluebird

Gritstone Oncology Inc. (Emeryville, Calif.) filed for an IPO on NASDAQ and announced a deal with bluebird bio Inc. (NASDAQ:BLUE) to develop cell therapies using natural T cell receptors (TCRs) against tumor-specific targets. Gritstone filed on...
20:04 , Aug 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Alt-neoantigens

Neoantigens derived from alternative splicing could broaden the target space for cancer vaccines and T cell therapies, according to two studies published this month. While questions remain about whether they are sufficiently immunogenic to create...
20:37 , Aug 23, 2018 |  BC Extra  |  Company News

Gritstone files for IPO, forges deal with bluebird

Gritstone Oncology Inc. (Emeryville, Calif.) filed for an IPO on NASDAQ and announced a deal with bluebird bio Inc. (NASDAQ:BLUE) to develop cell therapies using natural T cell receptors (TCRs) against tumor-specific targets. Gritstone filed to...
15:35 , Jun 12, 2018 |  BC Innovations  |  Translation in Brief

A glioblastoma feature story

The Ivy Glioblastoma Atlas Project has added anatomically based expression patterns to the growing body of transcriptional atlases, and the results are being used to pinpoint intratumor regions as therapeutic targets. Led by the Allen Institute...
21:46 , Apr 25, 2018 |  BC Innovations  |  Translation in Brief

Prostate prognosis

A Dana-Farber Cancer Institute team has uncovered previously unreported associations between prostate cancer and low-frequency mutations in 79 genes that could serve as prognostic markers for metastatic disease. The results, published this month in Nature Genetics,...
18:52 , Mar 15, 2018 |  BC Innovations  |  Tools & Techniques

Shared burden

Having learned their lesson with PD-L1, companies are collaborating on assay standards for tumor mutation burden -- a likely contender for the next major biomarker in immuno-oncology. A Friends of Cancer Research-led consortium of pharmas...
18:02 , Mar 12, 2018 |  BioCentury  |  Regulation

Stretching accelerated approval

FDA wants to stretch its accelerated approval pathway beyond traditional surrogate endpoints to include overall survival that has been demonstrated in small trials, such as exploratory studies. The change is a response to advances in...
19:45 , Mar 2, 2018 |  BC Extra  |  Politics & Policy

Volume of comments delays Foundation coverage decision

After missing the Feb. 28 decision date, the Centers for Medicare & Medicaid Services (CMS) said it will "soon" issue a final National Coverage Determination (NCD) for next-generation sequencing (NGS) cancer diagnostics, including FoundationOne CDx...
17:33 , Mar 2, 2018 |  BC Week In Review  |  Financial News

Synthetic biology play Senti emerges with $53M series A

Senti Biosciences Inc. (South San Francisco, Calif.) announced a tranched $53 million series A round led by existing investor New Enterprise Associates (NEA). 8VC, Amgen Ventures, Pear Ventures, Lux Capital, Menlo Ventures, Allen & Co.,...
12:35 , Feb 27, 2018 |  BC Extra  |  Financial News

Synthetic biology play Senti debuts with $53M series A

Senti Biosciences Inc. (South San Francisco, Calif.) announced a tranched $53 million series A round led by existing investor New Enterprise Associates (NEA). 8VC, Amgen Ventures, Pear Ventures, Lux Capital, Menlo Ventures, Allen & Co.,...